Cowen reaffirmed their buy rating on shares of Alector (NASDAQ:ALEC) in a research note issued to investors on Wednesday, AnalystRatings.com reports.
NASDAQ ALEC opened at $18.84 on Wednesday. Alector has a 52 week low of $15.16 and a 52 week high of $27.00. The company has a quick ratio of 7.92, a current ratio of 7.92 and a debt-to-equity ratio of 0.16. The stock has a 50-day moving average price of $18.56.
Alector (NASDAQ:ALEC) last posted its earnings results on Monday, May 13th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.12). The business had revenue of $5.61 million for the quarter. As a group, equities analysts expect that Alector will post -1.38 earnings per share for the current year.
Alector Company Profile
Alector, Inc, a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease.
Featured Story: Average Daily Trade Volume – ADTV
Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.